Pharma Deals Review, Vol 2010, No 7 (2010)

Font Size:  Small  Medium  Large

Shire to Acquire Movetis and Expand its Gastrointestinal Portfolio

Heather Cartwright

Abstract


Shire has made a conditional offer for the Belgian speciality gastrointestinal (GI) company Movetis valued at US$565 M (€428 M). The deal, which includes rights to the recently launched constipation drug Resolor® (prucalopride) in Europe, will enhance Shire’s GI portfolio.



Add comment

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.